Stati Uniti - Ingliż - NLM (National Library of Medicine)

lansinoh laboratories, inc. - drug facts dimethicone 5.0%  usp modified lanolin 15.5 %   zinc oxide 5.5 % datos del medicamento   dimeticona 5.0%  lanolina modificada 15.5%, calidad usp   oxido de zinc 5.5% - skin protectant protector de la piel treats diaper rash   protects skin  promotes healing trata la irritacion por el panal  protege la piel  ayuda a sanar

Stati Uniti - Ingliż - NLM (National Library of Medicine)

lansinoh laboratories inc - lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - stop use and ask a doctor if ■ condition worsens ■ symptoms persist for more than 7 days ■ symptoms clear up and return within a few day stop use and ask a doctor if ■ condition worsens ■ symptoms persist for more than 7 days ■ symptoms clear up and return within a few days for external use only topical analgesic

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

lansinoh (uk) ltd - wool fat - cutaneous ointment - 1mg/1mg

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

lansinoh (uk) ltd - wool fat - cutaneous cream - 1mg/1mg

Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

lansinoh (uk) ltd - wool fat - cutaneous cream - 1mg/1mg

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

egnell ameda limited - wool fat - ointment

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

key pharmaceuticals pty ltd - 35337 - shield, nipple, reusable - a cover used to protect the nipple of a nursing woman

Panama - Ingliż - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sandoz gmbh, kundl - oxaliplatino - oxaliplatino....50.00 mg. / oxaliplatino....100.00 mg.

Panama - Ingliż - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

fresenius kabi oncology limited - oxaliplatino - oxaliplatino....5,00 mg

Stati Uniti - Ingliż - NLM (National Library of Medicine)

corden pharma latina s.p.a. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - platinol-aq (cisplatin injection) is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of platinol-aq and cyclophosphamide. platinol-aq, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received platinol-aq therapy. platinol-aq is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. platinol-aq is contraindicated in patients with preexisting renal impairme